Takeda Pharmaceutical Company Limited

Fraunhofer-gesellschaft Zur Foerderung Der Angewandten Forschung E.v.

Amgen Research (munich) Gmbh

Takeda Gmbh

Amgen Research Gmbh

Markus Rast

Gerhard Becker

Henning Gieseler

Wolfgang Ise

Peter Skufca

Christian De Muynck

Gerhard Pohlmann

Peter Iwatschenko

Wolfgang Koch

Horst Windt

Pernille Dybendal Pedersen

Wolfram Steinhilber

Thomas Urbig

Jürgen Volz

Thomas Boehm

Friedemann Taut

Daniela Rahmel

Sergio Rodriguez-morillas

Tomomine Iida

Jurgen Volz

The present invention relates to a bacteriophage composition comprising at least one bacteriophage species, at least one α-linked polymeric glucose and at least one polyol. In certain embodiments, the α-linked polymeric glucose has a mean molecular weight of greater than 10 kDa.

Bacteriophage compositions

The present invention provides a method for preparation of a lyophilized formulation of an anti-CD 20 antibody as well as to a lyophilized formulation of an anti-CD 20 antibody, comprising an anti-CD 20 antibody and having a residual moisture content in the range of 1% to 10%. The present invention also relates to the reconstituted formulation obtained by the method described herein, the use of said antibody formulation as a medicament, the use of the lyophilized formulation for the preparation of a medicament and a method of treating a patient.

Formulation of an antibody and use thereof

The present invention relates to aqueous formulations comprising at least 20 mg/ml of a compound neutralizing GM-CSF, a lyoprotectant and an amino acid and/or a buffer. The ingredients of the formulation preferably provide stability to the compound neutralizing GM-CSF in view of lyophilization, storage and reconstruction. In a preferred aspect, the formulation, e.g. after reconstruction, is for use in therapy, preferably for use in the treatment of inflammatory and autoimmune disorders, preferably including allergic and psoriatic disorders, as well as arthritic and asthmatic disorders. Furthermore, a kit comprising the formulation of the invention is provided.

Lyophilized formulation comprising GM-CSF neutralizing compound

The invention relates to aerosolized and humidified particles comprising a therapeutically active substance which can be obtained by suspending dry inhalable particles in a carrier gas, adding water vapor and causing condensation of water on the particles. The invention further relates to methods to generate these particles, and apparatus useful to carry out such methods.

Humidified particles comprising a therapeutically active substance

Growing community of inventors

Radolfzell, Germany

Markus Rast